Novel Modalities & Drug Delivery
Strategic Advisory for Novel Modalities and Drug Delivery Innovation
Novel modalities and next-generation drug delivery platforms represent the most exciting and operationally complex frontier in biopharma today.
The science is advancing faster than most organizations can build the commercial, regulatory, and manufacturing infrastructure to support it. The companies that succeed in novel modalities are not always the ones with the best science. They are the ones that combine scientific ambition with operational discipline.
At Katogen, we help companies developing novel modalities and innovative drug delivery systems navigate that gap — bringing 35+ years of hands-on biopharma operator experience to the strategic, regulatory, and commercial challenges that define this space.
What We Do
Modality Strategy and Portfolio Positioning We help leadership teams build a clear strategic rationale for their modality choice — and position that rationale compellingly for investors, acquirers, and partners who need to understand why this platform, why now, and why your team.
Regulatory Pathway Navigation Novel modalities operate under evolving FDA guidance frameworks. We help companies identify the right regulatory pathway, anticipate the questions regulators will ask, and build the evidence package needed to support approval.
Manufacturing and CMC Strategy Novel therapeutics can require specialized manufacturing infrastructure that most CDMOs are still building. We help companies identify the right manufacturing partners, negotiate CDMO relationships, and build CMC strategies that will survive acquisition diligence.
Commercial Readiness for Novel Therapeutics Launching a novel modality is not like launching a conventional drug. Payer education, site-of-care strategy, patient identification, and specialist engagement all require approaches that are specific to the modality. We help companies build commercial strategies that reflect that reality.
Drug Delivery Innovation Strategy For companies developing novel drug delivery platforms — including extended-release, targeted delivery, and next-generation formulation technologies — we provide strategic advisory on platform positioning, IP strategy, partnership development, and commercialization planning.
Who This Is For
CEOs and executive teams at biopharma and biotech companies developing novel therapeutics, or innovative drug delivery platforms — at any stage from early development through pre-commercialization.
Why Katogen
We have built and scaled biopharma organizations across multiple modalities and therapeutic areas. We understand the operational complexity of novel modalities from the inside — not as observers, but as operators.